BIIB 023

Drug Profile

BIIB 023

Alternative Names: Anti-TWEAK monoclonal antibody - Biogen; BIIB-023

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action TNFSF12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscular atrophy
  • Discontinued Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 26 Oct 2015 Discontinued - Phase-I for Rheumatoid arthritis in Russia, Ukraine, USA (IV)
  • 26 Oct 2015 Discontinued - Preclinical for Rheumatoid arthritis in USA (SC)
  • 21 Oct 2015 Discontinued - Phase-I for Lupus nephritis (In volunteers) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top